These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23340178)

  • 1. Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines.
    Hartmann S; Günther N; Biehl M; Katzer A; Kuger S; Worschech E; Sukhorukov VL; Krohne G; Zimmermann H; Flentje M; Djuzenova CS
    Cancer Lett; 2013 May; 331(2):200-10. PubMed ID: 23340178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
    Djuzenova CS; Blassl C; Roloff K; Kuger S; Katzer A; Niewidok N; Günther N; Polat B; Sukhorukov VL; Flentje M
    Cancer Biol Ther; 2012 Apr; 13(6):425-34. PubMed ID: 22286776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities.
    Memmel S; Sisario D; Zöller C; Fiedler V; Katzer A; Heiden R; Becker N; Eing L; Ferreira FLR; Zimmermann H; Sauer M; Flentje M; Sukhorukov VL; Djuzenova CS
    Oncotarget; 2017 Jul; 8(28):45298-45310. PubMed ID: 28424411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
    Ueno T; Tsukuda K; Toyooka S; Ando M; Takaoka M; Soh J; Asano H; Maki Y; Muraoka T; Tanaka N; Shien K; Furukawa M; Yamatsuji T; Kiura K; Naomoto Y; Miyoshi S
    Lung Cancer; 2012 Apr; 76(1):26-31. PubMed ID: 21996088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
    Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
    Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
    Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
    Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
    Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
    Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.
    Lee KH; Lee JH; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Cancer Sci; 2011 Jul; 102(7):1388-95. PubMed ID: 21453385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.
    Stühmer T; Zöllinger A; Siegmund D; Chatterjee M; Grella E; Knop S; Kortüm M; Unzicker C; Jensen MR; Quadt C; Chène P; Schoepfer J; García-Echeverría C; Einsele H; Wajant H; Bargou RC
    Leukemia; 2008 Aug; 22(8):1604-12. PubMed ID: 18480838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
    Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
    Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitizing tumor cells to radiation by targeting the heat shock response.
    Schilling D; Kühnel A; Konrad S; Tetzlaff F; Bayer C; Yaglom J; Multhoff G
    Cancer Lett; 2015 May; 360(2):294-301. PubMed ID: 25721082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.
    Stingl L; Niewidok N; Müller N; Selle M; Djuzenova CS; Flentje M
    Strahlenther Onkol; 2012 Jun; 188(6):507-15. PubMed ID: 22441439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.
    Massey AJ; Schoepfer J; Brough PA; Brueggen J; Chène P; Drysdale MJ; Pfaar U; Radimerski T; Ruetz S; Schweitzer A; Wood M; Garcia-Echeverria C; Jensen MR
    Mol Cancer Ther; 2010 Apr; 9(4):906-19. PubMed ID: 20371713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
    Okui T; Shimo T; Hassan NM; Fukazawa T; Kurio N; Takaoka M; Naomoto Y; Sasaki A
    Anticancer Res; 2011 Apr; 31(4):1197-204. PubMed ID: 21508365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
    Moser C; Lang SA; Hackl C; Wagner C; Scheiffert E; Schlitt HJ; Geissler EK; Stoeltzing O
    Anticancer Res; 2012 Jul; 32(7):2551-61. PubMed ID: 22753713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
    Gaspar N; Sharp SY; Eccles SA; Gowan S; Popov S; Jones C; Pearson A; Vassal G; Workman P
    Mol Cancer Ther; 2010 May; 9(5):1219-33. PubMed ID: 20457619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
    Canonici A; Qadir Z; Conlon NT; Collins DM; O'Brien NA; Walsh N; Eustace AJ; O'Donovan N; Crown J
    Invest New Drugs; 2018 Aug; 36(4):581-589. PubMed ID: 29396630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.